Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2011

Oxford Medical Diagnostics Obtains $1.61M Financing

  • Oxford Medical Diagnostics (OMD), the developer of breath-based tests for metabolic and infectious diseases, reports raising £981,000 (roughly $1.61 million). The funding will be used in the development of its device for the diagnosis and monitoring of type 1 and 2 diabetes.

    By next year, the company aims to bring to market a point-of-care diagnostic that detects the volatile gas acetone, which is reportedly a known marker for both types of diabetes. This test is based on OMD’s CEAS (cavity enhanced absorption spectroscopy) and PES (plasma emission spectroscopy) technologies, and the company is also working on diagnostics for infectious diseases.

    OMD says that it has raised £2.2 million to date. The company also generates revenue from its gas analysis service segment. Besides the CEAS and PES platforms, OMD’s technologies included broadband CEAS. The firm says that it recently signed an R&D agreement with gas analyst specialist Michell Instruments of Ely.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »